> All the R&D budget slashing in Big Pharma would seem to suggest a rise in demand for CROs, but Forbes warns that the expected growth may not be so robust. Article
> Quintiles is eyeing partnerships with two large Chicago hospitals, likely looking to conduct clinical trials there. Story
> PPD is expanding its cGMP cell-based assay laboratory, looking to meet a growing demand in the development of biosimilars and novel drugs. News
> SK Biopharmaceuticals, a drug developer spun out of South Korean conglomerate SK Holdings, is working with Chinese CROs PKU International HealthCare Group and Shanghai Medicilon to develop SKL-PSY, a treatment for depression and bipolar disorder. Item
> ACRO is asking the FDA for clarifications on draft guidance the group says paints a murky picture of how CROs should manage the transition to electronic trial data. More